stockportfolio.pro
GILD vs VRTX: Which Stock Is the Better Buy?
Gilead Sciences, Inc. and Vertex Pharmaceuticals Incorporated side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — GILD vs VRTX, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Gilead Sciences, Inc. (GILD) | Vertex Pharmaceuticals Incorporated (VRTX) | |
|---|---|---|
| Market cap | $163.0B | $134.0B |
| Revenue (latest FY) | $29.44B | $12.00B |
| Net income (latest FY) | $8.51B | $3.95B |
| Revenue growth (5y CAGR) | 3.6% | 14.1% |
| Net margin | 28.9% | 32.9% |
| Return on equity | 37.5% | 21.2% |
| P/E ratio | 17.9 | 31.4 |
| Dividend yield | 2.5% | — |
| Profitable years (of last 10) | 10 | 8 |
| Positive free cash flow | Yes | Yes |
See the full GILD vs VRTX breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open GILD's full financials → Open VRTX's full financials →More comparisons
Frequently asked questions
Which is bigger, GILD or VRTX?
Gilead Sciences, Inc. is larger by market capitalization — $163.0B versus $134.0B.
Which grows faster, GILD or VRTX?
Over the last five fiscal years, Vertex Pharmaceuticals Incorporated grew revenue faster — 14.1%/yr versus 3.6%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.